Plain Language Summaries (PLS): The New Mandate in Regulatory Submissions (EU/FDA).

Healthcare communication is undergoing a fundamental transformation. Regulators, researchers, and the public increasingly expect clinical research findings to be understandable not only to scientists but also to patients and communities affected by those studies. As a result, Plain Language Summaries have become an essential component of modern scientific communication.

Plain Language Summaries (PLS) translate complex clinical and regulatory information into accessible language without compromising scientific accuracy. In the European Union, legislative changes have established formal requirements for lay summaries of clinical trials. In the United States, the Food and Drug Administration (FDA) continues to advance patient-focused communication initiatives that align with many of the same principles. Understanding these developments is now a core competency for professional medical writers.

Why Plain Language Summaries Matter in Modern Healthcare Communication

Scientific transparency is no longer limited to publishing in peer-reviewed journals. Patients, caregivers, advocacy organizations, and the general public increasingly seek direct access to research findings.

Plain Language Summaries support this goal by:

• Improving public understanding of clinical research.
• Enhancing trust between sponsors and participants.
• Promoting ethical dissemination of study results.
• Supporting patient engagement and informed decision-making.
• Strengthening organizational transparency.

Unlike scientific abstracts, which target healthcare professionals, PLS are designed for readers without specialized medical knowledge. They avoid technical jargon, define essential concepts, and explain the practical significance of study findings.

The rise of patient-centered healthcare has made accessible communication a strategic and ethical priority across the pharmaceutical and research sectors.

Effective scientific communication includes both expert audiences and the public.

Plain Language Summaries in EU Regulatory Submissions

The European Union has become a global leader in promoting clinical trial transparency.

The EU Clinical Trials Regulation

The European Union Clinical Trials Regulation (EU CTR 536/2014) requires sponsors to prepare a summary of clinical trial results understandable to laypersons. These summaries are intended to make research outcomes accessible to trial participants and the wider public.

The regulation recognizes that individuals who contribute to clinical research deserve clear information about the studies in which they participate.

Clinical Trials Information System (CTIS)

The Clinical Trials Information System (CTIS) provides a centralized platform for clinical trial information across the European Union.

Lay summaries submitted through CTIS are expected to:

• Use plain, non-technical language.
• Explain the purpose of the study.
• Describe participant characteristics.
• Summarize key findings.
• Present safety information appropriately.
• Explain the significance of the results.

Beyond Regulatory Compliance

For many organizations, PLS has evolved from a compliance exercise into a broader communication strategy that supports public trust and corporate responsibility.

In the EU, lay summaries are an established regulatory expectation under the Clinical Trials Regulation.

The FDA Perspective on Plain Language Summaries

The regulatory environment in the United States differs from that of the European Union.

Patient-Focused Drug Development

The FDA has expanded efforts to incorporate the patient perspective into medical product development through its Patient-Focused Drug Development (PFDD) initiative.

These efforts emphasize:

• Clear communication.
• Patient engagement.
• Accessible health information.
• Transparency throughout the product lifecycle.

Current Regulatory Position

Unlike the EU, the FDA does not currently impose a universal requirement for Plain Language Summaries for all regulatory submissions.

However, pharmaceutical companies increasingly produce PLS voluntarily to:

• Support patient engagement.
• Improve public understanding.
• Align with global transparency standards.
• Meet expectations from journals and advocacy groups.

Future Direction

Many experts anticipate continued growth in patient-centered regulatory communication. As international standards evolve, organizations that develop robust PLS capabilities are likely to be better positioned for future requirements.

The FDA promotes patient-centered communication, although it does not currently mandate universal PLS requirements comparable to the EU framework.

Best Practices for Writing Effective Plain Language Summaries

Creating a successful PLS requires specialized medical writing expertise.

Understand the Target Audience

A PLS should be written for readers with little or no scientific background.

Writers should:

• Identify likely reader needs.
• Avoid assumptions about medical knowledge.
• Focus on practical meaning rather than technical complexity.

Use Clear and Accessible Language

Best practices include:

• Short sentences.
• Active voice.
• Common vocabulary.
• Limited abbreviations.
• Definitions for unavoidable medical terms.

Organize Information Logically

An effective structure often includes:

1. Why was the study conducted?
2. Who participated?
3. What treatments were studied?
4. What were the main findings?
5. What side effects occurred?
6. What do the results mean?

Maintain Scientific Accuracy

Simplification should never distort evidence.

Medical writers must ensure that:

• Numerical data remain accurate.
• Benefits and risks are presented fairly.
• Limitations are acknowledged.
• Uncertainty is communicated honestly.

Collaborate Across Teams

High-quality PLS development often involves collaboration among:

• Medical writers.
• Regulatory affairs specialists.
• Clinical scientists.
• Patient engagement experts.
• Legal and compliance teams.

The best PLS combine scientific rigor with genuine accessibility.

Challenges and Opportunities for Medical Writers

The growing adoption of PLS is reshaping the role of regulatory and scientific communicators.

Balancing Accuracy and Simplicity

The greatest challenge is reducing complexity without losing meaning. Oversimplification can introduce inaccuracies, while excessive technical language defeats the purpose of a PLS.

Managing Global Standards

Organizations operating internationally may need to satisfy multiple regulatory expectations and cultural contexts simultaneously.

Addressing Health Literacy

Health literacy varies widely across populations. Writers should consider readability, cultural sensitivity, and accessibility for diverse audiences.

Expanding Professional Opportunities

Demand for professionals skilled in patient-centered communication continues to grow.

Medical writers with expertise in:

• Regulatory writing,
• Health literacy,
• Clinical research communication, and
• Ethical publication practices

are becoming increasingly valuable across the life sciences industry.

Plain Language Summaries represent both a communication challenge and a significant opportunity for specialized medical writers.

Conclusion

Plain Language Summaries are transforming how clinical research is communicated. They reflect a broader movement toward transparency, patient engagement, and ethical dissemination of scientific information.

The European Union has established formal expectations for lay summaries through its Clinical Trials Regulation, while the FDA continues to strengthen patient-focused communication initiatives. Together, these developments signal a future in which accessible scientific communication becomes an integral part of the regulatory landscape.

For medical writers and regulatory professionals, mastering PLS is no longer a niche skill. It is an essential capability that combines scientific expertise with public responsibility.

Explore more expert guides on the MedLexis Blog and discover MedLexis services for professional medical writing, regulatory communication, and evidence-based health content.